Floatz logo

Tocilizumab

Diffuse Astrocytoma, IDH-Wildtype

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Diffuse Astrocytoma, IDH-Wildtype cohort.

Asset / SponsorPhaseRating
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
Carboplatin
Novartis Pharmaceuticals
Phase 2B
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2B
Temsirolimus
National Cancer Institute (NCI)
Phase 1/2CCC

View all 20 →

Same molecule, other indications

Tocilizumab is also rated in:

rheumatoid arthritisDormant
BB
Indicative ·
66 / 100
View asset →
COVID-19Dormant
BB
Indicative ·
65 / 100
View asset →
acute chest syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →